世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の抗真菌薬市場 2018-2022年

Global Antifungal Drugs Market 2018-2022

IRTNTR23954

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年12月US$2,500
シングルユーザライセンス
97

サマリー

この調査レポートは世界の抗真菌薬市場を分析・予測したTechNavioの市場調査報告書です。

Description

About this market
Use of antifungal infections is expected to drive growth in the market. Research has shown synergism between many antifungals, which has led to an increase in clinicians prescribing combination therapies over monotherapies. Also, availability of antifungals with novel mechanisms of actions has promoted the trend of using combinations. Technavio’s analysts have predicted that the antifungal drugs market will register a CAGR of over 3% by 2022.
Market Overview
Increase in antifungal research funding
An increase in funding for antifungal research is another key factor contributing to the growth of the global antifungal drugs market. In many European countries, government funding is also available for research in fungal diseases.
Diagnostic challenges due to non-specific symptoms
Antifungals are often associated with mild adverse effects like itching, redness, abdominal pain, and diarrhea.
For the detailed list of factors that will drive and challenge the growth of the antifungal drugs market during the 2018-2022, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Merck and Pfizer the competitive environment is quite intense. Factors such as the use of antifungal infections and the increase in antifungal research funding, will provide considerable growth opportunities to antifungal drugs manufactures. Astellas Pharma, Basilea Pharmaceutica, Merck, and Pfizer are some of the major companies covered in this report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: PIPELINE ANALYSIS
- Fungal infection pipeline
PART 06: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION
- Segmentation by route of administration
- Comparison by route of administration
- Topical - Market size and forecast 2017-2022
- Oral - Market size and forecast 2017-2022
- Parenteral - Market size and forecast 2017-2022
- Market opportunity by product
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Vendors covered
PART 15: VENDOR ANALYSIS
- Market positioning of vendors
- Astellas Pharma
- Basilea Pharmaceutica
- Merck
- Pfizer
PART 16: APPENDIX
- List of abbreviations


Exhibit 01: Parent market
Exhibit 02: Global antifungals treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Late-stage pipeline drugs against fungal infections
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global antifungal drugs market - Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global antifungal drugs market - Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Route of administration - Market share 2017-2022 (%)
Exhibit 20: Comparison by route of administration
Exhibit 21: Topical - Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Topical - Year-over-year growth 2018-2022 (%)
Exhibit 23: Oral - Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Oral - Year-over-year growth 2018-2022 (%)
Exhibit 25: Parenteral - Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Parenteral - Year-over-year growth 2018-2022 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Global antifungal drugs market - Market share by geography 2017-2022 (%)
Exhibit 30: Regional comparison
Exhibit 31: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 32: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 33: Top 3 countries in Americas
Exhibit 34: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 35: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in EMEA
Exhibit 37: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 38: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Market opportunity
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: Vendor overview
Exhibit 47: Astellas Pharma - Business segments
Exhibit 48: Astellas Pharma - Organizational developments
Exhibit 49: Astellas Pharma - Geographic focus
Exhibit 50: Astellas Pharma - Key offerings
Exhibit 51: Vendor overview
Exhibit 52: Basilea Pharmaceutica - Business segments
Exhibit 53: Basilea Pharmaceutica - Organizational developments
Exhibit 54: Basilea Pharmaceutica - Geographic focus
Exhibit 55: Basilea Pharmaceutica - Key offerings
Exhibit 56: Vendor overview
Exhibit 57: Merck - Business segments
Exhibit 58: Merck? Organizational developments
Exhibit 59: Merck - Geographic focus
Exhibit 60: Merck - Segment focus
Exhibit 61: Merck - Key offerings
Exhibit 62: Vendor overview
Exhibit 63: Pfizer - Business segments
Exhibit 64: Pfizer - Organizational developments
Exhibit 65: Pfizer - Geographic focus
Exhibit 66: Pfizer - Segment focus
Exhibit 67: Pfizer - Key offerings


?

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る